Loading...
XNASKRRO
Market cap1.29bUSD
Jan 10, Last price  
35.26USD
1D
-6.27%
1Q
-8.82%
IPO
127.78%
Name

Frequency Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:KRRO chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
19.52%
Rev. gr., 5y
6.31%
Revenues
0k
0028,947,00036,984,00014,068,00000
Net income
-81m
L+39.87%
-20,237,000-19,168,000-18,746,000-26,511,000-21,959,000-58,032,000-81,172,000
CFO
-67m
L+25.42%
-14,614,000-17,024,00034,215,000-45,188,000-32,094,000-53,645,000-67,283,000
Earnings
Mar 24, 2025

Profile

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
URL
https://www.frequencytx.com/
IPO date
Oct 03, 2019
Employees
46
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
88,164
61,509
Unusual Expense (Income)
NOPBT
(88,164)
(61,509)
NOPBT Margin
Operating Taxes
27
10
Tax Rate
NOPAT
(88,191)
(61,519)
Net income
(81,172)
39.87%
(58,032)
164.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
117,250
62
BB yield
Debt
Debt current
1,991
2,921
Long-term debt
64,423
3,339
Deferred revenue
Other long-term liabilities
1,053
163,863
Net debt
(103,142)
(53,529)
Cash flow
Cash from operating activities
(67,283)
(53,645)
CAPEX
(7,836)
(5,212)
Cash from investing activities
11,164
11,060
Cash from financing activities
187,761
18
FCF
(119,116)
(66,268)
Balance
Cash
166,150
55,248
Long term investments
3,406
4,541
Excess cash
169,556
59,789
Stockholders' equity
(182,997)
(101,674)
Invested Capital
387,168
169,636
ROIC
ROCE
EV
Common stock shares outstanding
1,529
255
Price
Market cap
EV
EBITDA
(84,534)
(58,998)
EV/EBITDA
Interest
118
Interest/NOPBT